// App-Quantinova.ai

MON-395 : FGF-2 Increases Resistance to Doxorubicin-Induced Cardiac Injury

Researchers

Presenter

  • David Sontag

Principal Investigators

  • Elissavet Kardami

  • Thomas Netticadan

  • Peter A Cattini

Medical Centers

  • Canadian Centre for Agri-Food Research in Health and Medicine, Winnipeg, Canada

  • Institute of Cardiovascular Research, Winnipeg, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Ischemia-reperfusion injury

  • Cardiotoxicity

  • Coronary Artery Disease

Biomarkers

  • Basic fibroblast growth factor

Drug/Treatment

  • chelerythrine

  • Doxorubicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved